CRISPR/Cas9 and AAV mediated insertion of β2 microglobulin-HLA-G fusion gene protects mesenchymal stromal cells from allogeneic rejection and potentiates the use for off-the-shelf cell therapy

INTRODUCTION: Mesenchymal stromal cells (MSCs) hold the potential for application as cellular therapy products; however, there are many problems that need to be addressed before the use in clinical settings, these include the heterogeneity of MSCs, scalability in MSC production, timing and technique...

Descripción completa

Detalles Bibliográficos
Autores principales: Meshitsuka, Sohsuke, Ninomiya, Ryo, Nagamura-Inoue, Tokiko, Okada, Takashi, Futami, Muneyoshi, Tojo, Arinobu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Japanese Society for Regenerative Medicine 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9582586/
https://www.ncbi.nlm.nih.gov/pubmed/36313397
http://dx.doi.org/10.1016/j.reth.2022.09.009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9582586/
https://www.ncbi.nlm.nih.gov/pubmed/36313397
http://dx.doi.org/10.1016/j.reth.2022.09.009

Ejemplares similares